NASDAQ$LQDA
Liquidia Corporation · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported full year financial results and provided a corporate update.
Liquidia Corporation reported its full year 2023 financial results, with a net loss of $78.5 million. The company is preparing for the commercial launch of YUTREPIA following favorable court decisions and awaiting final FDA approval.
- Invalidity of sole patent supporting injunction was affirmed in appeal proceedings at the Federal Circuit.
- Awaiting final FDA approval of YUTREPIA to treat PAH and PH-ILD after March 31, 2024.
- Advancing industry leading portfolio for inhaled treprostinil between YUTREPIA and sustained-release program, L606.
- Cash and cash equivalents totaled $83.7 million as of December 31, 2023.
Headline financials
Revenue & EPS history
Liquidia · Revenue · Quarterly
$4.53M
Revenue by segment
Liquidia · $3.7M total across 1 segment · Q3 2023
- Promotion Agreement$3.7M+15.6%100.0%
Forward guidance
Liquidia is preparing to become a full-scale commercial entity in 2024 and initiate meaningful change to the lives of patients diagnosed with PAH and PH-ILD.
Tailwinds
- Positioned to be ready for launch of YUTREPIA in both indications following the expiration of Tyvaso’s market exclusivity on March 31, 2024.
- Confident that the medical community will see first-hand that YUTREPIA has the potential to not only be the best in class inhaled product.
- YUTREPIA has a convenient, low-effort delivery and wide dosing range enabled by our proprietary PRINT Technology.
- Liquidia plans to complete enrollment of all 60 patients in ASCENT study in 2024 and will share interim data at upcoming conferences.
- Preparing to initiate the global PH-ILD study by the end of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+3.4%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+3.5%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+31.8%
Q2 2022
Best reaction
-13.3%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.4% | +34.5% | +54.1% | |
| Q4 2025 | +0.4% | +12.9% | +9.6% | |
| Q3 2025 | +8.8% | +7.1% | +38.5% | |
| Q1 2025 | -1.0% | +3.0% | +16.8% | |
| Q4 2024 | +1.2% | +6.2% | -6.9% | |
| Q3 2024 | -5.6% | -7.6% | +2.7% | |
| Q2 2024 | +2.9% | +10.4% | -17.7% | |
| Q1 2024 | -0.8% | +5.4% | +10.4% | |
| Q4 2023 | +9.6% | +11.3% | -0.2% | |
| Q3 2023 | -1.0% | -4.4% | +9.8% | |
| Q2 2023 | -6.3% | -8.9% | -7.5% | |
| Q1 2023 | +5.0% | +7.8% | +26.1% | |
| Q4 2022 | +13.5% | +13.2% | +6.3% | |
| Q3 2022 | +0.8% | -0.4% | +14.6% | |
| Q2 2022 | +31.8% | +34.5% | +9.9% | |
| Q1 2022 | +7.7% | +21.9% | -17.0% | |
| Q4 2021 | +11.2% | +9.7% | -17.8% | |
| Q3 2021 | +9.9% | +9.7% | +3.1% | |
| Q2 2021 | -0.8% | +11.8% | +16.4% | |
| Q1 2021 | -0.7% | +0.0% | -0.7% | |
| Q4 2020 | -7.4% | -6.6% | +2.2% | |
| Q3 2020 | +0.7% | -12.7% | -36.9% | |
| Q2 2020 | -13.3% | -8.5% | -23.3% | |
| Q1 2020 | +8.0% | +8.7% | +13.4% | |
| Q4 2019 | -1.5% | +1.7% | +54.5% | |
| Q3 2019 | +5.2% | +0.6% | +6.4% | |
| Q2 2019 | +6.4% | -0.7% | -40.6% | |
| Q1 2019 | -3.0% | -0.4% | +2.6% | |
| Q4 2018 | +3.0% | +3.1% | -43.8% | |
| Q3 2018 | -9.2% | -1.3% | +19.4% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro